

07th November 2025

To
The Corporate Relations Department
BSE Limited
Phiroz Jeejeebhoy Towers, 25th Floor,
Dalal Street,
Mumbai- 400001
Scrip Code - 543308
ISIN: INE967H01025

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051
Symbol - KIMS
ISIN: INE967H01025

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 07th November 2025 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further to our intimation of the Board Meeting dated 24th October 2025, the Board of Directors, at its meeting held today, has approved the following:

- a) Unaudited (Standalone and Consolidated) financial results of the Company for the 02nd quarter and half-year ended 30th September 2025 together with the Limited Review Reports as reviewed by the Audit Committee.
- b) Approval of merger of wholly-owned subsidiaries KIMS Hospitals Private Limited (Transferor Company-1) and Chalasani Hospitals Private Limited (Transferor Company-2) with its Holding Company i.e. Krishna Institute of Medical Sciences Limited (Transferee Company).

Further, the financial results are also available on the website of the Company at [https://www.kimshospitals.com/investors/Disclosures under Regulation 46 of SEBI \(LODR\) Regulations, 2015/ Financial Information/ Financial Result](https://www.kimshospitals.com/investors/Disclosures_under_Regulation_46_of_SEBI_(LODR)_Regulations,2015/_Financial_Information/_Financial_Result) and on the websites of BSE Ltd and National Stock Exchange of India Ltd viz. www.bseindia.com and www.nseindia.com, respectively.

Further, the financial results will also be published in the newspaper as per the requirement and in the format prescribed under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Board Meeting Commenced at : 11:30 A.M

Board Meeting Concluded at : 02:30 P.M

Thanking you,

For Krishna Institute of Medical Sciences Limited

NAGAJAYANTHI
JUTTUR
RAGHAVENDRA DAS
Digitally signed by
NAGAJAYANTHI JUTTUR
RAGHAVENDRA DAS
Date: 2025.11.07 14:33:25
+05'30'

Nagajayanthi J.R

Company Secretary & Compliance Officer

Krishna Institute of Medical Sciences Limited

D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com
CIN: L55101TG1973PLC040558

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to****The Board of Directors****Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate for the quarter ended September 30, 2025 and year to date from April 01, 2025 to September 30, 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S.No.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Hospital Bengaluru Private Limited	Subsidiary
10	Sarvejana Healthcare Private Limited	Subsidiary
11	SPANV Medisearch Lifesciences Private Limited	Subsidiary
12	KIMS Manavata Hospitals Private Limited	Subsidiary
13	Meda Institute of Podiatry Private Limited	Subsidiary
14	Chalasani Hospitals Private Limited	Subsidiary
15	Kondapur Healthcare Limited	Associate



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
- Three subsidiaries, whose unaudited interim financial results include total assets of Rs. 3,042 million as at September 30, 2025, total revenues of Rs. 248 million and Rs. 471 million, total net loss after tax of Rs. 51 million and Rs. 108 million, total comprehensive loss of Rs. 52 million and Rs. 109 million, for the quarter ended September 30, 2025 and the period ended on that date respectively, and net cash outflows of Rs. 50 million for the period from April 01, 2025 to September 30, 2025, as considered in the Statement which have been reviewed by their respective independent auditors.
 - An associate, whose unaudited interim financial results include Group's share of net loss of Rs. Nil and Rs. Nil and Group's share of total comprehensive loss of Rs. Nil and Rs. Nil for the quarter ended September 30, 2025 and for the period from April 01, 2025 to September 30, 2025 respectively, as considered in the Statement whose interim financial results, other financial information have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries and associate is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 is not modified with respect to our reliance on the work done and the reports of the other auditors.

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

Navneet Rai

per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 25102328BMQCL6186

Place: Bengaluru

Date: November 07, 2025



Statement of Unaudited Consolidated Financial Results for the quarter and half year ended 30 September 2025

		(Rupees in millions)					
		Quarter Ended			Half year ended		Year ended
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	30-Sep-24	31-Mar-25
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	(a) Revenue from operations	9,607	8,716	7,773	18,323	14,657	30,351
	(b) Other income	42	71	50	113	96	319
	Total Income	9,649	8,787	7,823	18,436	14,753	30,670
2	Expenses						
	(a) Purchase of medical consumables, drugs and surgical instruments	2,035	1,917	1,566	3,952	3,014	6,404
	(b) Increase in inventories of medical consumables, drugs and surgical instruments	(83)	(77)	(11)	(160)	(33)	(135)
	(c) Employee benefits expense	1,745	1,510	1,192	3,255	2,378	4,995
	(d) Other expenses	3,870	3,440	2,845	7,310	5,323	11,258
	(e) Finance costs	450	326	199	776	378	903
	(f) Depreciation and amortisation expenses	661	534	410	1,195	800	1,772
	Total Expenses	8,678	7,650	6,201	16,328	11,860	25,197
3	Profit before share of loss from associate (1-2)	971	1,137	1,622	2,108	2,893	5,473
4	Share of loss from associate, net of tax	-	-	-	-	-	-
5	Profit before tax and exceptional items (3+4)	971	1,137	1,622	2,108	2,893	5,473
6	Exceptional items	(3)	-	-	(3)	-	108
7	Profit before tax (5+6)	968	1,137	1,622	2,105	2,893	5,581
8	Tax expense						
	(a) Current tax	377	324	448	701	786	1,495
	(b) Deferred tax credit	(129)	(37)	(33)	(166)	(52)	(62)
	Total tax expenses (8)	248	287	415	535	734	1,433
9	Profit for the period/year (7-8)	720	850	1,207	1,570	2,159	4,148
	Attributable to:						
	Owners of the company	669	786	1,074	1,455	1,940	3,845
	Non controlling interests	51	64	133	115	219	303
10	Other comprehensive (loss)/ income for the period/year						
	Items that will not be reclassified subsequently to statement of profit and loss						
	- Re-measurement (loss)/gain on defined benefit plans	4	(6)	(31)	(2)	(30)	(31)
	- Income tax effect	(1)	1	8	-	8	8
	Other comprehensive (loss)/ income, net of tax	3	(5)	(23)	(2)	(22)	(23)
	Attributable to:						
	Owners of the company	2	(4)	(20)	(2)	(19)	(20)
	Non controlling interests	1	(1)	(3)	-	(3)	(3)
11	Total comprehensive income (9+10)						
	Owners of the company	671	782	1,054	1,453	1,921	3,825
	Non controlling interests	52	63	130	115	216	300
	Total comprehensive income for the period/year	723	845	1,184	1,568	2,137	4,125
12	Paid up equity share capital (face value of Rs.2 each)						800
13	Other Equity						20,578
14	Earnings per share (of Rs.2 each): (not annualised for the quarter/period ended)						
	(a) Basic (Rs.)	1.67	1.96	2.68	3.64	4.85	9.61
	(b) Diluted (Rs.)	1.67	1.96	2.68	3.64	4.85	9.61

Notes:

- The above statement of unaudited consolidated financial results of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") and its associate, have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). These results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 07 November 2025. The Statutory Auditors have expressed an unmodified opinion on the consolidated financial results.
- Exceptional items pertain to valuation of call option under the call option agreements executed by the Group to acquire a majority equity stake in entities with whom the Group has Operations and Management agreements to operate and manage their hospitals.
- The Unaudited Consolidated Balance sheet and Unaudited Consolidated Statement of Cash Flows are set out in Annexure I and Annexure II respectively.
- The Group operates in one single reportable business segment- "Medical and Healthcare services".
- The above Unaudited Consolidated Financial Results of the Group are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

Bengaluru
07 November 2025



For and on behalf of the Board
Krishna Institute of Medical Sciences Limited

Dr. B. Bhaskara Rao
Managing Director
DIN: 00008985

Krishna Institute of Medical Sciences Limited

Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Consolidated Unaudited Balance Sheet as at 30 September 2025

(Rupees in millions)			
S.No	Particulars	As at 30 September 2025 (Unaudited)	As at 31 March 2025 (Audited)
A	ASSETS		
1	Non-current Assets		
	Property, plant and equipment	35,016	21,988
	Capital work-in-progress	5,734	12,138
	Goodwill	3,386	3,386
	Other Intangible assets	586	677
	Right-of-use assets	7,431	7,434
	Investments accounted for using equity method	775	765
	Financial assets		
	(i) Investments	6	6
	(ii) Loans	74	55
	(iii) Other financial assets	1,017	601
	Deferred tax asset (net)	868	599
	Non-current tax assets (net)	555	438
	Other non-current assets	2,572	2,300
	Total Non-current Assets - (1)	58,020	50,387
2	Current Assets		
	Inventories	800	640
	Financial assets		
	(i) Investments	201	220
	(ii) Trade receivables	4,844	3,954
	(iii) Cash and cash equivalents	807	560
	(iv) Bank balances other than (iii) above	193	237
	(v) Loans	301	477
	(vi) Other financial assets	543	508
	Other current assets	544	377
	Total Current Assets - (2)	8,233	6,973
3	Total Assets (3) = (1)+(2)	66,253	57,360
B	EQUITY AND LIABILITIES		
4	Equity		
	Equity share capital	800	800
	Other equity	21,904	20,578
	Equity attributable to Shareholders of the company - (4)	22,704	21,378
5	Non-controlling interests - (5)	3,056	2,810
6	Total Equity (6) = (4)+(5)	25,760	24,188
7	Non-current liabilities		
	Financial liabilities		
	(i) Borrowings	20,170	16,541
	(ii) Lease liabilities	6,526	6,331
	(iii) Other financial liabilities	822	778
	Other non-current liabilities	574	357
	Provisions	372	335
	Deferred tax liabilities (net)	572	468
	Total Non-current liabilities - (7)	29,036	24,810
8	Current liabilities		
	Financial liabilities		
	(i) Borrowings	4,938	2,519
	(ii) Lease liabilities	236	176
	(iii) Trade payables		
	(a) Total outstanding dues of micro enterprises and small enterprises; and	448	150
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	2,846	2,541
	(iv) Other financial liabilities	1,952	2,158
	Other current liabilities	689	538
	Provisions	272	264
	Current tax liabilities (net)	76	16
	Total Current liabilities - (8)	11,457	8,362
9	Total Equity and Liabilities (9) = (6)+(7)+(8)	66,253	57,360



Krishna Institute of Medical Sciences Limited
Corporate Identity number : L55101TG1973PLC040558
Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Consolidated Cash flows for the half year ended 30 September 2025

(Rupees in millions)

Particulars	For the half year ended	For the half year ended
	30-Sep-25	30-Sep-24
	(Unaudited)	(Unaudited)
I. Cash flows from operating activities:		
Profit before tax for the period	2,105	2,893
Adjustments for operating activities:		
Depreciation and amortisation expenses	1,195	800
Finance costs	776	378
Loss on sale of property, plant and equipment (net)	3	13
Provision of expected credit loss for trade receivables (including bad debts)	34	201
Interest income	(47)	(39)
Deferred Government grants income	(16)	-
Liabilities no longer required written back	(3)	-
Gain on mutual funds	(4)	(35)
Rental income	(7)	(2)
Loss on fair valuation of Call option (net)	3	-
Operating cash flows before working capital changes	4,039	4,209
Adjustments for:		
(Increase)/Decrease		
- In Trade receivables	(924)	(935)
- in Inventories	(160)	(33)
- in Other financial assets and other assets	(246)	(701)
Increase in trade payables, other financial liabilities, provisions and other liabilities	894	597
Cash generated from operations	3,603	3,137
Income taxes paid, net of refunds	(757)	(676)
Net cash generated from operating activities (1)	2,846	2,461
II. Cash flows from investing activities		
Acquisition of property, plant and equipment and intangible assets	(7,532)	(3,750)
Proceeds from sale of property, plant and equipment	136	21
Investment in associate	(10)	(27)
Acquisition of subsidiaries	-	(1,123)
Investment in mutual funds	(840)	(1,540)
Proceeds from sale of mutual funds	863	2,271
Loans given	(207)	(390)
Loans repayment received	364	-
Redemption of bank deposits (having original maturity of more than three months)	116	22
Investment in bank deposits (having original maturity of more than three months)	(80)	(186)
Rental income received	7	2
Interest received	19	5
Net cash used in investing activities (2)	(7,165)	(4,695)
III. Cash flows from financing activities		
Proceeds from long-term borrowings	5,232	3,217
Repayment of long-term borrowings	(1,197)	(115)
Proceeds from short-term borrowings (net)	2,014	310
Issue of shares to non-controlling interest	243	-
Acquisition of non-controlling interest	(239)	(253)
Share application money received from non-controlling interest	115	-
Advance paid for acquisition of non-controlling interest	(360)	(79)
Payment of principal of lease liability	(25)	(16)
Payment of interest on lease liability	(265)	(141)
Interest paid	(952)	(530)
Net cash flows generated from financing activities (3)	4,566	2,393
Net Increase in cash and cash equivalents (1+2+3)	247	159
Cash and cash equivalents acquired through business combination	-	4
Cash and cash equivalents at the beginning of the period	560	469
Cash and cash equivalents at the end of the period	807	632
Components of cash and cash equivalents		
Cash on hand	46	41
Balances with banks		
- On current accounts	761	310
- In deposit accounts (with original maturity of 3 months or less)		281
Total	807	632




Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended September 30, 2025 and year to date from April 01, 2025 to September 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

per Navneet Rai Kabra
Partner

Membership No.: 102328

UDIN: 25102328 BM06CK5850

Place: Bengaluru

Date: November 07, 2025



Statement of Unaudited Standalone Financial Results for the quarter and half year ended 30 September 2025

		(Rupees in millions)					
		Quarter ended			Half year ended		Year ended
		30-Sep-25 (Unaudited)	30-Jun-25 (Unaudited)	30-Sep-24 (Unaudited)	30-Sep-25 (Unaudited)	30-Sep-24 (Unaudited)	31-Mar-25 (Audited)
1	Income						
	(a) Revenue from operations	4,300	3,734	3,633	8,034	6,907	13,841
	(b) Other income	125	122	66	247	119	567
	Total Income	4,425	3,856	3,699	8,281	7,026	14,408
2	Expenses						
	(a) Purchase of medical consumables, drugs and surgical instruments	917	781	691	1,698	1,336	2,795
	(b) (Increase)/decrease in inventories of medical consumables, drugs and surgical instruments	(63)	(23)	19	(86)	9	(42)
	(c) Employee benefits expense	761	682	596	1,443	1,211	2,364
	(d) Other expenses	1,563	1,319	1,216	2,882	2,302	4,559
	(e) Finance costs	178	125	46	303	84	232
	(f) Depreciation and amortisation expenses	205	175	140	380	277	577
	Total Expenses	3,561	3,059	2,708	6,620	5,219	10,485
3	Profit before tax and exceptional items (1-2)	864	797	991	1,661	1,807	3,923
4	Exceptional items	(3)	-	-	(3)	-	108
5	Profit before tax (3+4)	861	797	991	1,658	1,807	4,031
6	Tax expense						
	(a) Current tax	187	174	293	361	511	951
	(b) Deferred tax charge/(credit)	39	35	(24)	74	(33)	51
	Total tax expenses	226	209	269	435	478	1,002
7	Profit for the period/year (5-6)	635	588	722	1,223	1,329	3,029
8	Other comprehensive (loss)/income for the period/year						
	Items that will not be reclassified subsequently to statement of profit and loss						
	- Re-measurement (loss)/gain on defined benefit plans	-	(4)	(20)	(2)	(19)	(18)
	- Income tax effect	-	1	5	1	5	5
	Other comprehensive (loss)/income, net of tax	2	(3)	(15)	(1)	(14)	(12)
9	Total comprehensive income for the period/year (7+8)	637	585	707	1,222	1,315	3,016
10	Paid up equity share capital (face value of Rs.2 each)						800
11	Other Equity						20,880
12	Earnings per share (of Rs.2 each) : (not annualised for the quarter /period ended)						
	(a) Basic (Rs.)	1.59	1.47	1.80	3.06	3.32	7.57
	(b) Diluted (Rs.)	1.59	1.47	1.80	3.06	3.32	7.57

Notes:

- The above statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company"), have been prepared in accordance with the Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). These results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 07 November 2025. The Statutory Auditors have expressed an unmodified opinion on the standalone financial results.
- Exceptional items pertains to valuation of call option under the call option agreements executed by the Company to acquire a majority equity stake in entities with whom the Company has Operations and Management agreements to operate and manage their hospitals.
- The Unaudited Standalone Balance sheet and Unaudited Standalone Statement of Cash Flows are set out in Annexure I and Annexure II respectively.
- The Company operates in one single reportable business segment- "Medical and Healthcare services".
- The above Unaudited Standalone Financial Results of the Company are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf of the Board
Krishna Institute of Medical Sciences Limited

Bengaluru
07 November 2025



Krishna Institute of Medical Sciences Limited

Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Unaudited Standalone Balance Sheet as at 30 September 2025

		(Rupees in millions)	
	Particulars	As at 30 September 2025 (Unaudited)	As at 31 March 2025 (Audited)
A	ASSETS		
1	Non-current Assets		
	Property, plant and equipment	13,016	7,238
	Capital work-in-progress	919	5,303
	Intangible assets	184	208
	Right-of-use assets	286	287
	Financial assets		
	(i) Investments	12,707	12,258
	(ii) Loans	4,415	2,761
	(iii) Other financial assets	848	278
	Other non-current assets	360	564
	Total Non-current Assets - (1)	32,735	28,897
2	Current Assets		
	Inventories	349	263
	Financial assets		
	(i) Investments	200	-
	(ii) Trade receivables	2,442	1,874
	(iii) Cash and cash equivalents	295	261
	(iv) Bank balances other than (iii) above	31	34
	(v) Loans	67	70
	(vi) Other financial assets	299	304
	Other current assets	296	188
	Total Current Assets - (2)	3,979	2,994
3	Total Assets (3) = (1)+(2)	36,714	31,891
B	EQUITY AND LIABILITIES		
4	Equity		
	Equity share capital	800	800
	Other equity	22,102	20,880
	Total Equity - (4)	22,902	21,680
5	Non-current liabilities		
	Financial liabilities		
	(i) Borrowings	7,233	5,771
	(ii) Other financial liabilities	46	26
	Provisions	222	207
	Other non-current liabilities	260	228
	Deferred tax liabilities (net)	467	392
	Total Non-current liabilities - (5)	8,228	6,624
6	Current liabilities		
	Financial liabilities		
	(i) Borrowings	3,290	1,309
	(ii) Trade payables		
	(a) Total outstanding dues of micro enterprises and small enterprises; and	121	52
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	1,075	892
	(iii) Other financial liabilities	442	833
	Other current liabilities	440	346
	Provisions	147	139
	Current tax liabilities (net)	69	16
	Total Current liabilities - (6)	5,584	3,587
	Total Equity and Liabilities (7) = (4)+(5)+(6)	36,714	31,891



Krishna Institute of Medical Sciences Limited

Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Standalone Cashflows for the half year ended 30 September 2025

(Rupees in millions)

Particulars	For the half year ended	
	30-Sep-25	30-Sep-24
	(Unaudited)	(Unaudited)
I. Cash flows from operating activities:		
Profit before tax for the period	1,658	1,807
Adjustments for operating activities:		
Depreciation and amortisation expense	380	277
Profit on sale of property, plant and equipment (net)	(7)	(3)
Provision of expected credit loss for trade receivables (including bad debts)	25	132
Guarantee commission income	-	(6)
Interest income	(214)	(76)
Deferred Government grants income	(16)	-
Loss on fair valuation of Call option (net)	3	-
Gain on Mutual funds	(0)	(28)
Finance costs	303	84
Operating cash flows before working capital changes	2,132	2,187
Adjustments for:		
(Increase)/decrease		
- in trade receivables	(593)	(466)
- in inventories	(86)	9
- in other financial assets and other assets	(146)	(139)
Increase in trade payables, other financial liabilities, provisions and other liabilities	369	360
Cash generated from operations	1,676	1,951
Income taxes paid, net of refunds	(306)	(401)
Net cash generated from operating activities (1)	1,370	1,550
II. Cash flows from investing activities		
Acquisition of property, plant and equipment and intangible assets	(1,868)	(1,332)
Proceeds from sale of property, plant and equipment	15	10
Investment in subsidiaries	(142)	(1,307)
Advance for investment in subsidiary	(260)	(70)
Investment in mutual funds	(470)	(950)
Proceeds from sale of mutual funds	270	1,594
Loans given to subsidiaries	(2,212)	(1,735)
Loans repaid by subsidiaries	593	675
Redemption of bank deposits (having original maturity of more than three months)	13	1
Investment in bank deposits (having original maturity of more than three months)	(10)	(40)
Interest received	32	135
Net cash flows used in investing activities (2)	(4,446)	(3,028)
III. Cash flows from financing activities		
Proceeds from long-term borrowings	1,939	1,345
Repayment of long-term borrowings	(279)	(7)
Proceeds from short-term borrowings (net)	1,783	285
Interest paid	(333)	(171)
Net cash flows generated from financing activities (3)	3,110	1,452
Net increase/(decrease) in cash and cash equivalents (1+2+3)	34	(26)
Cash and cash equivalents at the beginning of the period	261	205
Cash and cash equivalents at the end of the period	295	179
Components of cash and cash equivalents		
Cash on hand	31	21
Balances with banks		
On current accounts	264	157
In deposit accounts	-	6
Total	295	179

